Prednisone Use in Pregnancy
Prednisone is safe to use during pregnancy when clinically indicated, but should be maintained at ≤10 mg/day (or tapered to <20 mg/day with addition of steroid-sparing agents if higher doses are needed) to minimize maternal and fetal risks while controlling disease activity. 1
Safety Profile
Prednisone and other nonfluorinated glucocorticoids are pregnancy-compatible medications that do not cause major birth defects or teratogenicity. 2 The key consideration is balancing disease control against dose-dependent maternal and fetal complications. 2
Recommended Dosing Strategy
Low-Dose Maintenance (Preferred)
- Continue prednisone at ≤10 mg/day if clinically indicated throughout pregnancy. 1
- This dose range carries minimal risk for maternal-fetal complications. 2
- Low-dose exposure (≤5 mg/day prednisone-equivalent) confers the lowest overall risk profile. 2
Moderate-to-High Dose Requirements
- Taper doses >20 mg/day to <20 mg/day of prednisone, adding pregnancy-compatible steroid-sparing agents if necessary. 1
- Pregnancy-compatible steroid-sparing options include hydroxychloroquine, azathioprine, sulfasalazine, and certolizumab (which has minimal placental transfer). 1
- Calcineurin inhibitors (tacrolimus, cyclosporine) can also be considered as steroid-sparing agents. 1
Severe or Life-Threatening Disease
- For organ-threatening or life-threatening maternal disease, intravenous methylprednisolone pulse therapy is preferred over prolonged high-dose oral regimens. 2
- This approach minimizes cumulative glucocorticoid exposure while providing maximal disease control. 2
Dose-Dependent Risks
High-Dose Exposure (>5 mg/day prednisone-equivalent)
- Increased risk of gestational diabetes requiring screening throughout pregnancy. 2
- Elevated risk of serious maternal infections necessitating vigilant monitoring. 2
- Higher rates of preterm birth, particularly with cumulative doses early in gestation. 2, 3
- Pregnancy-related osteoporosis with prolonged exposure. 2
- In California Medicaid data, high cumulative dose trajectories in early pregnancy (before gestational day 140) were associated with preterm birth rates of 32.7% in asthma patients versus 14.0% with no exposure. 3
- Women with rheumatoid arthritis in the highest daily dose trajectory group delivered 2.3 weeks earlier than those in the lowest dose group. 4
Timing Considerations
- Early pregnancy exposure (first 139 days) to higher doses poses greater risk for preterm birth than later exposure. 3
- For asthma patients, higher doses early in pregnancy were associated with increased preterm birth, but doses after day 139 showed no clear association. 3
- Prednisone exhibits dose- and concentration-dependent pharmacokinetics during pregnancy, with apparent oral clearance increasing with higher doses. 5
Gestational Timing Restrictions
Third Trimester Considerations
- Avoid NSAIDs entirely in the third trimester due to risk of premature ductus arteriosus closure. 1
- If NSAIDs are needed in first two trimesters, use nonselective NSAIDs over COX-2 inhibitors due to limited data on the latter. 1
Delivery Planning
- Routine stress-dose glucocorticoids are NOT recommended for vaginal delivery. 1
- Stress-dose glucocorticoids ARE recommended for cesarean delivery. 1
Monitoring Requirements
All pregnant patients on glucocorticoids require:
- Screening for gestational diabetes throughout therapy. 2
- Vigilant monitoring for signs of infection. 2
- Regular assessment for preterm labor risk. 2
Breastfeeding Compatibility
Prednisone is compatible with breastfeeding, with minimal infant exposure. 5
- Breast milk-to-plasma ratios are 0.5-0.6 for prednisone and 0.02-0.03 for prednisolone. 5
- Relative infant doses are 0.35-0.53% for prednisone and 0.09-0.18% for prednisolone. 5
Long-Term Pediatric Outcomes
Children exposed to prednisone in utero demonstrate reassuring long-term outcomes. 2
- Normal developmental milestones in follow-up studies. 2
- No increased risk of insulin resistance in exposed children. 2
Common Pitfalls to Avoid
- Do not use fluorinated glucocorticoids (dexamethasone, betamethasone) for maternal disease control, as these cross the placenta more readily; reserve them only for fetal indications. 1
- Do not abruptly discontinue prednisone after long-term use; taper gradually to avoid adrenal insufficiency. 6
- Do not use standard Medrol Dosepaks (starting at 24 mg/day ≈ 30 mg prednisone) for prolonged periods, as this exceeds recommended maintenance thresholds. 2
- Do not delay adding steroid-sparing agents when doses cannot be tapered below 20 mg/day. 1